Gut Protein Expression in Immune Cells Linked to HIV Risk, Progression

Researchers recently uncovered a strong link between the prevalence of immune cells that express high levels of a gut-homing protein at HIV infection and related clinical outcomes, according to a study published by Science Translational Medicine.
 
The authors previously discovered a link between alpha-4 beta-7-expressing immune cells and HIV in monkey models of the infection.
 
In the current study, women whose CD4+ T cells had a high level of alpha-4 beta-7 on the surface were more likely to develop HIV compared with women who have fewer of these cells. Additionally, these patients were also more likely to experience rapid immune damage resulting from infection.
 
“Our findings suggest that having a high frequency of alpha-4 beta-7-expressing CD4+ T cells, which HIV preferentially infects, leads to more HIV-infected CD4+ T cells moving to the gut, which in turn leads to extensive damage to gut-based immune cells,” said co-author Anthony S. Fauci, MD, director of the National Institute of Allergy and Infectious Diseases.
 
Included in the study were blood samples from 59 women prior to HIV infection and 106 HIV-negative women. Patients were participants in the CAPRISA 004 study, which examined the efficacy of an HIV prevention treatment in sub-Saharan Africa.
 
The researchers compared the percentage of CD4+ T cells with high levels of alpha-4 beta-7 in the blood samples.
 
The number of immune cells with high levels of alpha-4 beta-7 was observed to have a moderate effect on HIV risk among both the general study population and among a cohort of 41 female sex workers in Kenya, according to the study.
 
The risk of HIV skyrocketed 18% for every 1% increase in alpha-4 beta-7 protein, which was similar to preclinical findings.
 
The number of the CD4+ T cells expressing high levels of alpha-4 beta-7 was also observed to strongly affect how quickly the immune system sustained damage. CD4+ T cell levels dropped twice as fast among patients with high pre-infection levels of alpha-4 beta-7 compared with patients who had lower levels, according to the study.
 
Notably, the HIV viral load a few months after infection was much higher among women with increased pre-infection levels compared with women who had lower pre-infection levels.
 
The authors hypothesize that the immune system damage was likely the result of HIV-related damage to the gut because higher pre-infection levels of alpha-4 beta-7 were linked to higher levels of a biomarker for gut damage.
 
Further investigation revealed that HIV targets CD4+ T cells expressing alpha-4 beta-7 early in the infection, especially in the gut, according to the study.
 
The authors then analyzed data from the RV254 clinical trial and discovered that early initiation of antiretroviral therapy (ART) was unable to prevent CD4+ T cells depletion from the gut or reconstitute the immune cells.
 
“These findings suggest that interventions in addition to ART may be needed to restore CD4+ T cells in the [gastrointestinal] tracts of people living with HIV,” said study co-lead Lyle McKinnon, PhD. “One such intervention could be an anti-alpha-4 beta-7 antibody called vedolizumab, which is FDA-approved for the treatment of ulcerative colitis and Crohn’s disease.”


Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Most Popular

Related Articles

Rates of hospital inpatient admissions before and during use of ivacaftor found that overall and cystic fibrosis-related inpatient admissions fell by 55% and 81%, respectively.
The development and uptake of antiretroviral therapy for HIV has reduced the risk of certain cancers were previously prevalent.
Only a small portion of latently infected cells are reactivated by latency-reversing agents.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.